Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

30 results about "Nicotine replacements" patented technology

Nicotine replacement therapy (NRT) is a medically-approved way to take nicotine by means other than tobacco. It is used to help with quitting smoking or stopping chewing tobacco.

Therapeutic composition and configuration

A system intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The system preferably comprises a lozenge incorporating the active ingredient, adapted toprovide oral administration of nicotine. The lozenge is in contact with a substrate (e.g., hollow tube) that can be manipulated within the mouth of the user (e.g., the hollow tube can be drawn upon tosimulate the inhalation of cigarette smoke). As such, the active ingredient is administered and the user is able to experience certain other physiological sensations. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy. The system comprising: a substrate portion (35) having an upstream end and a downstream end, the upstream end allowing for passage of drawn atmospheric air into the substrate and the downstream end adapted for positioning into a user's mouth for draw upon the substrate and inhalation of atmospheric air by the user, a lozenge portion (20) incorporating a source of active ingredient in a pharmaceutically acceptable form, the lozenge portion providing for oral ingestion of theactive ingredient, the lozenge portion and the substrate portion being physically separate from one another but in contact with each other, the lozenge being positioned at the downstream end of the substrate, and the lozenge and substrate portions being positioned so that the lozenge portion and a portion of the substrate portion can be located in the user's mouth during use, to provide for delivery of active ingredient from the lozenge and drawn air through the substrate.
Owner:NICONOVUM USA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products